Arrakis was founded in 2015 by Russell Petter, Ph.D., Alan Walts, Ph.D., Henri Termeer and Raj Parekh, Ph.D. with a vision to create a proprietary, transformational discovery platform that identifies small-molecule drugs that act directly on disease-causing RNA. The company was established with seed funding provided by Advent Life Sciences and Henri Termeer. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/27/17 | $38,000,000 | Series A |
Advent Life Sciences Canaan Partners  Celgene Corporation Henri Termeer Osage University Partners Pfizer Strategic Investments Group | undisclosed |
| 04/18/19 | $75,000,000 | Series B |
Advent Life Sciences Alexandria Venture Investments Canaan Partners Celgene Corporation GV HBM Healthcare Investments Nextech Invest Omega Funds Osage University Partners Pfizer Venture Investments VenBio WuXi AppTec | undisclosed |
